• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by MoonLake Immunotherapeutics

    4/21/26 4:31:24 PM ET
    $MLTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MLTX alert in real time by email
    DEFA14A 1 ny20067252x2_defa14a.htm DEFA14A
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    SCHEDULE 14A
    Proxy Statement Pursuant to Section 14(a) of the
    Securities Exchange Act of 1934
    (Amendment No.  )
     
     
     
     
    Filed by the Registrant
     
     
    ☒
    Filed by a Party other than the Registrant
     
     
     ☐
     
     
     
     
    Check the appropriate box:
     ☐
    Preliminary Proxy Statement
     ☐
    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
    ☐
    Definitive Proxy Statement
     ☒
    Definitive Additional Materials
     ☐
    Soliciting Material under §240.14a-12
     
    MoonLake Immunotherapeutics
     
    (Name of Registrant as Specified In Its Charter)
    (Name of Person(s) Filing Proxy Statement if other than the Registrant)
     
    Payment of Filing Fee (Check all boxes that apply):
    ☒
    No fee required.
     ☐
    Fee paid previously with preliminary materials.
     ☐
    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.


     Your Vote Counts!  *Please check the meeting materials for any special requirements for meeting attendance. At the meeting, you will need to request a ballot to vote these shares.  Smartphone users  Point your camera here and vote without entering a control number  For complete information and to vote, visit www.ProxyVote.com  Control #  V90809-P50459  MOONLAKE IMMUNOTHERAPEUTICS DORFSTRASSE 29  ZUG, SWITZERLAND 6300  MOONLAKE IMMUNOTHERAPEUTICS  2026 Annual General Meeting of Shareholders  Vote by June 3, 2026  11:59 PM ET  You invested in MOONLAKE IMMUNOTHERAPEUTICS and it’s time to vote!  You have the right to vote on proposals being presented at the Annual General Meeting of Shareholders. This is an important notice  regarding the availability of proxy materials for the shareholder meeting to be held on June 4, 2026.  Get informed before you vote  View the Notice, Proxy Statement and Annual Report online OR you can receive a free paper or email copy of the material(s) by  requesting prior to May 21, 2026. If you would like to request a copy of the material(s) for this and/or future shareholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to [email protected]. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.  Vote in Person at the Meeting*  June 4, 2026  8:00 a.m. Eastern Time  At the offices of Gibson, Dunn & Crutcher LLP Located at 200 Park Avenue  New York, New York 10166 
     

     Vote at www.ProxyVote.com  THIS IS NOT A VOTABLE BALLOT  This is an overview of the more complete proxy materials that are available to you on the Internet. You may view the proxy materials at www.ProxyVote.com or easily request a paper copy. We encourage you to access and review all of the important information contained in the proxy materials before voting.  Please follow the instructions on the reverse side to vote on these important matters.  Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”.  V90810-P50459  1. Election of the Class I director nominee to serve until the 2029 Annual General Meeting of Shareholders and until his successor is duly elected and qualified.  For  Nominee:  1a. Spike Loy  2. Ratification, by ordinary resolution, of the selection of Baker Tilly US, LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026.  For  3. Approval of, on a non-binding, advisory basis, the compensation of the Company’s named executive officers.  For  4. Approval of an amendment and restatement of the Company’s 2022 Equity Incentive Plan.  For  NOTE: Such other business as may properly come before the meeting or any adjournments or postponements thereof.  Voting Items  Board Recommends 
     
    Get the next $MLTX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MLTX

    DatePrice TargetRatingAnalyst
    3/23/2026$24.00Underperform → Outperform
    Wolfe Research
    3/19/2026$40.00Neutral → Buy
    Rothschild & Co Redburn
    1/15/2026$10.00Neutral → Sell
    Goldman
    1/9/2026$24.00Neutral → Buy
    BTIG Research
    11/3/2025$30.00Neutral → Buy
    H.C. Wainwright
    10/2/2025Buy → Neutral
    H.C. Wainwright
    10/1/2025$7.00Buy → Neutral
    Goldman
    9/30/2025$2.00Outperform → Underperform
    Wolfe Research
    More analyst ratings

    $MLTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Bodenstedt Matthias bought $98,808 worth of Class A ordinary shares (10,870 units at $9.09), increasing direct ownership by 2% to 627,536 units (SEC Form 4)

    4 - MoonLake Immunotherapeutics (0001821586) (Issuer)

    10/9/25 9:01:51 AM ET
    $MLTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chen Bihua bought $3,524,297 worth of Class A Ordinary Shares (58,839 units at $59.90) (SEC Form 4)

    4 - MoonLake Immunotherapeutics (0001821586) (Issuer)

    10/10/23 4:00:43 PM ET
    $MLTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chen Bihua bought $16,800,343 worth of Class A Ordinary Shares (293,212 units at $57.30) (SEC Form 4)

    4 - MoonLake Immunotherapeutics (0001821586) (Issuer)

    10/4/23 5:52:22 PM ET
    $MLTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MLTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    MoonLake Immunotherapeutics upgraded by Wolfe Research with a new price target

    Wolfe Research upgraded MoonLake Immunotherapeutics from Underperform to Outperform and set a new price target of $24.00

    3/23/26 8:23:40 AM ET
    $MLTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MoonLake Immunotherapeutics upgraded by Rothschild & Co Redburn with a new price target

    Rothschild & Co Redburn upgraded MoonLake Immunotherapeutics from Neutral to Buy and set a new price target of $40.00

    3/19/26 8:23:34 AM ET
    $MLTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MoonLake Immunotherapeutics downgraded by Goldman with a new price target

    Goldman downgraded MoonLake Immunotherapeutics from Neutral to Sell and set a new price target of $10.00

    1/15/26 8:33:55 AM ET
    $MLTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MLTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    MoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting

    Results from the Phase 3 VELA clinical trials in adults with moderate-to-severe hidradenitis suppurativa (HS) show that clinical responses continue to improve to Week 40, with 62% of patients treated with sonelokimab (SLK) achieving HiSCR75 and up to 32% of patients achieving HiSCR100 An analysis of different hallmark lesions of HS shows that up to 25% of patients achieved inflammatory remission at Week 40, defined as a 100% reduction in abscesses (A100), nodules (N100) and draining tunnels (DT100)Patients treated with SLK also showed substantial improvements in HiSQOL items at week 40 versus baseline, ranging from 41% (pain), to 54% (walking, getting dressed) to 62% (down or depressed)Up to

    3/28/26 3:00:00 PM ET
    $MLTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MoonLake Announces Positive Topline Results from its Phase 2 Clinical Trial of Sonelokimab in Axial Spondyloarthritis and Reports 2025 Financial Results

    In the Phase 2 S-OLARIS clinical trial in axial spondyloarthritis (axSpA), sonelokimab (SLK) demonstrated clinically meaningful benefit with 80+% of patients achieving ASAS40 by Week 12Consistently, other clinical and imaging scores also showed improvements of 80+% by week 12 for patients treated with SLK, including ASDAS-CRP and SPARCC MRIaxSpA is a disease driven by inflammation leading to irreversible ossification (via osteoblast activity) and ultimately to irreversible restriction of mobility – objective PET/MRI imaging data further showed a significant reduction in inflammation and osteoblast activity deep in affected joints, already by week 12, suggesting potential for disease modifica

    2/22/26 11:00:00 AM ET
    $MLTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ImageneBio Appoints Immunology Drug Development Veteran Dr. Ben Porter-Brown as Chief Medical Officer

    Brings 20+ years of clinical development experience in autoimmune and inflammatory diseases, including OX40/OX40L program leadership Will build and lead Imagene's clinical organization and drive completion of the Phase 2b ADAPTIVE trial in atopic dermatitis Will expand Phase 2b trial footprint with planned international sites including in the UK and Europe SAN DIEGO, Feb. 10, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (NASDAQ:IMA, "Imagene, " or the "Company")), today announced the appointment of Dr. Ben Porter-Brown, a seasoned autoimmune and inflammatory drug developer with experience in the OX40 receptor-ligand (OX40-OX40L) inhibition field, as its Chief Medical Officer. He will be fo

    2/10/26 7:00:00 AM ET
    $IMA
    $MLTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $MLTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Bodenstedt Matthias

    4 - MoonLake Immunotherapeutics (0001821586) (Issuer)

    4/16/26 4:10:22 PM ET
    $MLTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Santos Da Silva Jorge

    4 - MoonLake Immunotherapeutics (0001821586) (Issuer)

    4/14/26 5:55:59 PM ET
    $MLTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Bodenstedt Matthias

    4 - MoonLake Immunotherapeutics (0001821586) (Issuer)

    4/10/26 6:06:45 PM ET
    $MLTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MLTX
    SEC Filings

    View All

    SEC Form DEFA14A filed by MoonLake Immunotherapeutics

    DEFA14A - MoonLake Immunotherapeutics (0001821586) (Filer)

    4/21/26 4:31:24 PM ET
    $MLTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEF 14A filed by MoonLake Immunotherapeutics

    DEF 14A - MoonLake Immunotherapeutics (0001821586) (Filer)

    4/21/26 4:30:43 PM ET
    $MLTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by MoonLake Immunotherapeutics

    SCHEDULE 13D/A - MoonLake Immunotherapeutics (0001821586) (Subject)

    4/2/26 4:44:28 PM ET
    $MLTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MLTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by MoonLake Immunotherapeutics

    SC 13G/A - MoonLake Immunotherapeutics (0001821586) (Subject)

    11/12/24 10:32:13 AM ET
    $MLTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by MoonLake Immunotherapeutics

    SC 13D/A - MoonLake Immunotherapeutics (0001821586) (Subject)

    10/8/24 6:48:48 PM ET
    $MLTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by MoonLake Immunotherapeutics (Amendment)

    SC 13D/A - MoonLake Immunotherapeutics (0001821586) (Subject)

    3/5/24 4:59:16 PM ET
    $MLTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MLTX
    Leadership Updates

    Live Leadership Updates

    View All

    ImageneBio Appoints Immunology Drug Development Veteran Dr. Ben Porter-Brown as Chief Medical Officer

    Brings 20+ years of clinical development experience in autoimmune and inflammatory diseases, including OX40/OX40L program leadership Will build and lead Imagene's clinical organization and drive completion of the Phase 2b ADAPTIVE trial in atopic dermatitis Will expand Phase 2b trial footprint with planned international sites including in the UK and Europe SAN DIEGO, Feb. 10, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (NASDAQ:IMA, "Imagene, " or the "Company")), today announced the appointment of Dr. Ben Porter-Brown, a seasoned autoimmune and inflammatory drug developer with experience in the OX40 receptor-ligand (OX40-OX40L) inhibition field, as its Chief Medical Officer. He will be fo

    2/10/26 7:00:00 AM ET
    $IMA
    $MLTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $MLTX
    Financials

    Live finance-specific insights

    View All

    MoonLake Immunotherapeutics Reports Third Quarter 2025 Financial Results and Announces New Data from Clinical Trials of its Nanobody® Sonelokimab

    Ended the third quarter with $380.5 million in cash, cash equivalents and short-term marketable debt securities which, together with funds from a previously announced debt-facility, are expected to provide runway into the second half of 2027Reported results of its Phase 2 LEDA clinical trial in Palmoplantar Pustulosis (PPP) where sonelokimab (SLK) demonstrated clinically meaningful and statistically significant benefitReported an interim analysis of the long-term data from the VELA-1 and VELA-2 clinical trials in adults with Hidradenitis Suppurativa (HS), as well as an interim analysis of its VELA-TEEN clinical trial in adolescent HS, demonstrating the potential and competitive benefit of SL

    11/5/25 7:00:00 AM ET
    $MLTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MoonLake Immunotherapeutics Reports Second Quarter 2025 Financial Results and Provides a Business Update

    Phase 3 VELA program in hidradenitis suppurativa (HS) on track for an expected primary endpoint readout around September 2025 and an expected submission of a Biologic License Application (BLA) in the United States in mid-2026Other clinical trials of sonelokimab in palmoplantar pustulosis (PPP), axial spondyloarthritis (axSpA), psoriatic arthritis (PsA) and adolescent HS progressing well and expected to support a catalyst-rich roadmap over the next 12 monthsEnded the second quarter with $425.1 million in cash, cash equivalents and short-term marketable debt securities with up to an additional $425 million in non-dilutive funds remaining accessible through previously announced debt-facility Z

    8/5/25 7:00:00 AM ET
    $MLTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business Update

    MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business Update Continued to make significant progress with the development of the Nanobody® sonelokimab across portfolio of indications, including Phase 3 studies in hidradenitis suppurativa (HS), psoriatic Arthritis (PsA) and adolescent HS, as well as Phase 2 studies in palmoplantar pustulosis (PPP) and axial spondyloarthritis (axSpA)Announced completion of enrollment of patients in the Phase 3 program in HS (the VELA program) and disclosed baseline characteristics, replicating the Phase 2 MIRA trialPresented an interim readout of the Phase 2 LEDA study in PPP, highlighting the potential of sonelokimab

    5/12/25 4:00:00 PM ET
    $HTGC
    $MLTX
    Investment Managers
    Finance
    Biotechnology: Pharmaceutical Preparations
    Health Care